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Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have
increased graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). Bortezomib added to reduced-
intensity conditioning can offer beneﬁt in T cellereplete HLA-mismatched HSCT and may also beneﬁt
myeloablative conditioning (MAC) transplants. We conducted a phase II trial of short-course bortezomib plus
standard tacrolimus/methotrexate after busulfan/ﬂudarabine MAC in 34 patients with predominantly
myeloid malignancies. Fourteen (41%) received 8/8 HLA-matched unrelated donor (MUD) and 20 (59%)
received 7/8 HLA-mismatched related/unrelated donor peripheral blood stem cell grafts. Median age was 49
years (range, 21 to 60), and median follow-up was 25 months (range, 11 to 36). The regimen was well
tolerated. No dose modiﬁcations were required. Neutrophil and platelet engraftment occurred at a median of
14 (range, 10 to 33) and 17 (range, 10 to 54) days, respectively. Median 30-day donor chimerism was 99%
(range, 90 to 100), and 100-day grades II to IV and III to IV acute GVHD incidence was 32% and 12%
respectively. One-year chronic GVHD incidence was 50%. Two-year cumulative incidence of both NRM and
relapse was 16%. Two-year progression-free and overall survival rates were 70% and 71%, respectively.
Outcomes were comparable to an 8/8 MUD MAC cohort (n ¼ 45). Immune reconstitution was robust.
Bortezomib-based MAC HSCT is well tolerated, with HLA-mismatched outcomes comparable with 8/8 MUD
MAC HSCT, and is suitable for randomized evaluation. (clinicaltrials.gov: NCT01323920.)
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION donor (MUD) varies between racial and ethnic groups.
Allogeneic hematopoietic stem cell transplantation
(HSCT) is potentially curative in advanced or aggressive
hematologic malignancies. Whereas a sibling donor matched
at HLA-A, -B, -C, and -DRB1 is optimal, only about 30% of
patients who may beneﬁt from HSCT have such a donor
available [1]. The likelihood of ﬁnding a matched unrelateddgments on page 1912.
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ty for Blood and Marrow Transplantation.Accepting a 7/8 HLA match increases the likelihood of
identifying an adult donor for all, from the highest likelihood
group (whites of European descent [75%/97%]) to the
lowest likelihood group (blacks of South or Central American
descent [16%/66%]) [1], but at the expense of worse
outcomes. In myeloablative conditioning (MAC) HSCT,
observational studies comparing 7/8 versus 8/8 HLA MUDs
document an increased rate of 100-day severe grades III to IV
acute graft-versus-host disease (GVHD; 37% versus 28%) and
1- to 2-year nonrelapse mortality (NRM; 34% to 45% versus
22% to 36%), with worse progression-free survival (PFS; 38%
to 41% versus 47% to 52%) and overall survival (OS; 41% to 43%
versus 52% to 54%) [2-4].
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deplete proliferating alloreactive T lymphocytes, reduce Th1
cytokines, and block antigen presenting cell (APC) activation
[5,6]. Bortezomib may also spare regulatory T cells (Tregs)
that may be relevant in GVHD control [7]. Administered early
after stem cell infusion, bortezomib can control GVHD in
MHC-mismatched mouse HSCT and maintain therapeutic
graft-versus-tumor responses [8-10] while avoiding the
severe colonic toxicity that delayed or prolonged bortezomib
administration can induce in mice [9].
In a previous study of T cellereplete reduced-intensity
conditioning (RIC), we showed that a bortezomib-based
GVHD prophylaxis regimen (days þ1, þ4, and þ7 plus
standard-of-care tacrolimus/methotrexate [tac/MTX])
appeared to be safe and efﬁcacious in HLA-mismatched
HSCT, comparable with HLA-matched transplantation
[11,12]. Prospective, randomized, controlled trials of
bortezomib-based T cellereplete RIC HSCT are ongoing at the
national level (BMTCTN 1203). We therefore undertook a
phase II trial to determine whether bortezomib-based GVHD
prophylaxis is also effective with the more cytotoxic condi-
tioning regimen intensity in MAC HSCT using matched
unrelated and mismatched donors.
METHODS
This prospective, single-arm, phase II trial was approved by the insti-
tutional review board of the Dana-Farber Cancer Institute/Harvard Cancer
Center (DFCI 11-007). Written informed consent was obtained before
enrollment. (clinicaltrials.gov: NCT01323920.)
Trial Cohort
Participants with various hematologic malignancies aged 18 to 60 years
and lacking a timely 8/8 HLA-matched (-A, -B, -C, -DRB1) related donor
(MRD) received an 8/8 HLA-MUD or a 1-locus mismatched related or
unrelated donor (MMRD, MMUD). Participants with HIV infection, active
hepatitis B or C, abnormal renal (serum creatinine greater than the upper
limit of normal, creatinine clearance < 60 mL/min) or pulmonary (forced
expiratory volume in 1 second, forced vital capacity, or lung diffusing
capacity for carbon monoxide < 60%) or hepatic function (serum total bili-
rubin greater than the upper limit of normal, serum alanine or amino-
transferases more than 2 times upper limit of normal), Eastern Cooperative
Oncology Group performance status> 2, uncontrolled infections, peripheral
neuropathy  grade 2 within 21 days before, or history of seizures were
excluded. Enrollment time period was 2011 to 2012, and dataset was locked
May 1, 2014.
MAC comprisedﬂudarabine (40mg/m2 i.v.) and busulfan (130mg/m2 i.v.,
without pharmacokinetic (PK) dose adjustment) daily on days 7, 6, 5,
and 4. Target unmanipulated peripheral blood stem cell (PBSC) dose was
2  106 CD34þ cells/kg. GVHD prophylaxis comprised tacrolimus (starting
day3 toachievea target serum level of 5 to10ng/mL),MTX (15mg/m2 i.v. on
daysþ1, 10 mg/m2 i.v. on daysþ3,þ6, andþ11), and bortezomib (1.3 mg/m2
i.v. on days þ1, þ4, and þ7, in accordance with the standard 72-hour borte-
zomib dose interval). Tacrolimus taper commenced day þ100, with the goal
to be off immune suppression by day þ180 in the absence of GVHD.
Standard-of-Care Comparator Cohort
Clinical outcomes were also obtained for all adult hematologic malig-
nancy patients (n¼ 45) undergoing off-protocol 8/8MUD PBSCMACHSCTat
our center between 2010 and 2012 with standard-of-care tac/MTX pro-
phylaxis dosed similar to the study cohort (tacrolimus starting day3; MTX
on days þ1, þ3, þ6, and 11). Tacrolimus taper routinely commenced
around week 9, with the goal to be off immune suppression by 6 months in
the absence of GVHD. HSCT eligibility criteria were similar to those above.
MAC was composed of cyclophosphamide/total body irradiation (TBI).
Target PBSC dose was 2  106 CD34þ cells/kg. Median follow-up in sur-
vivors was 36 months (range, 13 to 49).
Supportive Care
Participants received ﬁlgrastim 5 mg/kg daily from day þ12 until an
absolute neutrophil count > 1000 cells/mL was attained and at least 12
months of Pneumocystis jiroveci and herpes simplex virus/varicella-zoster
virus prophylaxis. Antifungal prophylaxis was not routine.Immune Reconstitution Assays
CD4þ T cells were deﬁned as CD3þCD4þ; CD4þ naive cells were deﬁned
as CD4þ, CD45RO; CD4þ memory cells were deﬁned as CD4þCD45ROþ;
CD8þ T cells were deﬁned as CD3þCD8þ; CD8þ naive cells were deﬁned as
CD8þCD45ROCD62Lþ; CD8þmemory cells were deﬁned as CD8þCD45ROþ;
CD8þ terminal effector cells were deﬁned as CD8þCD45ROCD62L; CD4
Tregs were deﬁned as CD3þCD4þCD25med-highCD127low; natural killer (NK)
cells as CD56þCD3; and B cells as CD19þ. Fifty microliters of whole blood
(15% EDTA) in 5-mL polystyrene round-bottom reaction tubes were incu-
bated with ﬂuorophore-conjugated monoclonal antibodies: anti-CD3 V450
(clone UCHT1; BD Biosciences, San Jose, CA), anti-CD4 APC-H7 (clone RPA-
T4; BD Biosciences), anti-CD8 Paciﬁc-Orange (clone RPA-T8; Biolegend,
Dedham, MA), anti-CD25 PE-Cy7 (clone M-A251; BD Biosciences), anti-
CD127 PE-Cy5 (clone eBioRDR5; eBioscience, San Diego, CA), anti-CD62L
APC (clone DREG-56; BD Biosciences), CD45RO FITC (clone UCHL1; BD Bio-
sciences) for T cell subsets; anti-CD56 PE (clone B159; BD Biosciences), anti-
CD3 V450 (clone UCHT1; BD Biosciences) for NK/NKT cells; anti-CD19 APC
(clone HIB19; BD Biosciences) for B cells. RBC lysis with 500 mL 1 times BD
Pharm Lyse followed. Immune reconstitution ﬂow cytometry analysis used
FACSCanto II (BD Bioscience) and FACSDiva software (BD Bioscience).
Statistical Considerations
Baseline characteristics were reported descriptively. Neutrophil and
platelet engraftment was the number of days to absolute neutrophil count
500 cells/mL and platelet count  20,000 cells/mL, respectively, in the
absence of transfusions. Acute GVHD was graded per the consensus grading
system [13].
PFS was measured from the date of stem cell infusion to disease relapse/
progression or death. Patients alive without disease relapse/progression
were censored at the time last seen alive and progression-free. OS was
measured from the date of stem cell infusion to death from any cause.
Patients alive or lost to follow-up were censored at the time last seen alive.
PFS and OS were estimated by the method of Kaplan-Meier. The log-rank
test was used for comparisons of Kaplan-Meier curves.
Cumulative incidence of GVHD was constructed reﬂecting time to
relapse or death without GVHD as a competing event. Cumulative incidence
of NRM and relapse with or without death were constructed reﬂecting time
to relapse and time to nonrelapse death, respectively, as competing risks.
Difference between cumulative incidence curves in the presence of a
competing risk was tested using the Gray method [14]. Immunologic
parameters were analyzed descriptively and compared using the exact
Wilcoxon-rank-sum test.
All testing was 2-sided at the signiﬁcance level of .05, and multiple
comparisons were not adjusted. All calculations were done using SAS 9.3
(SAS Institute Inc, Cary, NC) and R version 2.13.2 (the Comprehensive R
Archive Network project, http://www.r-project.org).
RESULTS
Study Cohort
Thirty-four participants enrolled in the phase II study.
Baseline characteristics including diagnoses and disease risk
index are presented in Table 1. Most participants (27, 79%)
had myeloid disease. Median participant age was 49 years
(range, 21 to 60). Most received mismatched grafts. Fourteen
participants (41%) received 8/8 HLAMUD grafts, and 20 (59%)
received 1-locus HLA-mismatched grafts (18 MMUD, 2
MMRD) (Supplemental Table 1). Median follow-up time
among survivors was 25 months (range, 11 to 36).
One participant died on day 11 before engraftment. For
the remainder, the median time to neutrophil and platelet
engraftment time was 14 days (range, 10 to 33) and 17 days
(range, 10 to 54), respectively. Total nucleated cell donor
chimerism by day 30 was 99% (range, 90% to 100%) and by
day 100 was also 99% (range, 73% to 100%). The regimenwas
well tolerated. No bortezomib doses were missed or reduced
because of toxicity. No serious adverse events attributable to
bortezomib (eg, neuropathy) were documented. Non-
hematologic toxicities, with organ dysfunction (hepatic,
renal, pulmonary) and metabolic/endocrine abnormalities,
were anticipated after MAC HSCT. None experienced hepatic
veno-occlusive disease.
Six participants died without evidence of disease relapse/
progression, for a 2-year cumulative NRM incidence of 16%
Table 1
Baseline Characteristics of the Bortezomib Study Cohort (N ¼ 34)
Characteristic Mean Range
Age, yr 49 21-60
No. of Cases Percent
Age  50 16 47.1
Patient sex
Male 14 41.2
Female 20 58.8
Donor sex
Male 19 55.9
Female 15 44.1
Male patient and female donor 4 11.8
HLA typing at -A, -B, -C, -DRB1
8/8 MUD 14 41.2
7/8 Unrelated (MMUD) 18 52.9
Mismatch locus
A 8
B 1
C 6
DRB1 3
7/8 Related (MMRD) 2 5.9
Mismatch locus
A 1
DRB1 1
Diagnosis
AML 17 50
CML 1 2.9
MM/PCD 1 2.9
ALL 2 5.9
MDS 6 17.6
MPD 3 8.8
NHL 4 11.8
Graft source
PBSC 34 100
GVHD prophylaxis
Tac/bortezomib/MTX 34 100
Patient or donor CMV seropositivity
Yes 29 85.3
Disease risk index
Low 1 2.94
Intermediate 24 70.59
High 9 26.47
HCT-CI
0 15 44.1
1-2 9 26.5
3 10 29.4
AML indicates acute myelogenous leukemia; CML, chronic myelogenous leu-
kemia; MM/PCD, multiple myeloma/plasma cell dyscrasia; ALL, acute
lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPD, myelopro-
liferative disorder; NHL, non-Hodgkin lymphoma; CMV, cytomegalovirus;
HCT-CI, hematopoietic cell transplantationespeciﬁc comorbidity index.
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enterococcus/aspergillus infection, pneumonia/respiratory
failure, and gram-negative rod/gram-positive cocci sepsis, all
nonattributable to bortezomib. Five participants relapsed, for
a 2-year cumulative incidence of relapse of 16% (Figure 1A).
GVHD incidence was low, with 3 deaths. Grades II to IV acute
GVHD occurred in 13 participants, 5 of whom experienced
isolated upper gastrointestinal GVHD (gastrointestinal stage
1, overall grade II). The median time of grades II to IV acute
GVHD onset was 34 days (range, 16 to 181), with a 100-day
and 180-day cumulative incidence of 32% and 38%, respec-
tively (Figure 1B); 180-day cumulative incidence of grades II
to IV acute GVHD involving skin, liver, and/or lower gut was
24%. Four participants developed grades III to IV severe acute
GVHD (2 had grade IV acute GVHD), for a 180-day cumulative
incidence of 12%. Chronic GVHD occurred in 21 patients, with
a median time to onset of 241 days (range, 110 to 807). The
1-year cumulative incidence of chronic GVHD was 50%. Of
these, 18 had extensive chronic GVHD, for a 1-yearcumulative incidence of 41%. The 2-year PFS and OS rates
were 70% and 71%, respectively (Figure 1C).
Comparison with MUD MAC HSCT
Trial outcomes were retrospectively compared with a
near-contemporaneous standard-of-care MAC cohort (N ¼
45) from 2010 to 2012, receiving 8/8MUDwith Tcellereplete
PBSC grafts and tac/MTX GVHD prophylaxis. The cohorts
were similar with regards to diagnoses, patient sex,
donorerecipient sex match, cytomegalovirus serostatus,
disease risk index, and hematopoietic cell trans-
plantationespeciﬁc comorbidity index scores (Supplemental
Table 2). In the standard-of-care cohort, 1 patient died before
neutrophil engraftment and another died before platelet
engraftment. The median time to neutrophil engraftment
was 14 days (range, 11 to 60), comparable with the
bortezomib-based cohort (P ¼ .44), and the median time to
platelet engraftment was 20 days (range, 12 to 139), possibly
delayed compared with the bortezomib-based cohort (P ¼
.07). Despite older patients (P ¼ .02) and use of HLA-
mismatched grafts (P < .001) in the bortezomib-based
versus standard-of-care cohort, the cumulative incidence of
day 180 grades II to IV acute GVHD (38% [95% conﬁdence
interval {CI}, 22% to 54%] versus 56% [95% CI, 40% to 69%]; P¼
.044; Supplemental Figure 1) and cumulative incidence of
grades III to IV severe acute GVHD (12% [95% CI, 4% to 25%]
versus 27% [95% CI, 15% to 40%]; P ¼ .07) appeared to be
possibly lower in the presence of bortezomib. One-year
cumulative incidences of chronic GVHD and 2-year NRM
and relapse were similar. Importantly, 2-year PFS and OS
were similar despite use of HLA-mismatched transplantation
in the bortezomib-based cohort. Comparing the subset of
patients who received bortezomib-based 7/8 MMUD/MMRD
versus the 8/8 MUD standard-of-care MAC cohort also yiel-
ded similar outcomes (Supplemental Table 3).
Comparison of Bortezomib-MUD versus -MMUD/MMRD
Cohorts
We also compared MUD versus MMUD/MMRD outcomes
within the study cohort. The median time to engraft
neutrophils and platelets did not differ meaningfully. Median
day 30 and day 100 total nucleated cell chimerismwas 98% to
99% for both groups and time points. Two-year cumulative
incidence of NRM was 14% versus 15%, respectively (P ¼ .52)
(Figure 2A); 180-day cumulative incidence of GVHD was
possibly different, with grades II to IV acute GVHD involving
the skin, liver, and/or lower gut at 14% versus 30% and grades
III to IV severe acute GVHD of 7% versus 15%, respectively
(Figure 2B). However, this difference did not reach statistical
signiﬁcance (P ¼ .28 and .48, respectively). One-year cumu-
lative incidence of chronic GVHD was 57% versus 45% (P ¼
.40), and extensive chronic GVHD was 43% versus 40%,
respectively (P ¼ .74). Overall, the HLA-matched patients did
better than the mismatched patients, with a 2-year relapse
incidence of 0% versus 26%, respectively (P ¼ .044)
(Figure 2A), a 2-year PFS rate of 86% versus 59%, respectively
(P ¼ .03) (Figure 2C), and a 2-year OS rate of 86% versus 61%,
respectively (P ¼ .06) (Figure 2D).
Immune Reconstitution
In the bortezomib-based study cohort, the median total
CD3þ T cell count/mL at 1, 6, and 12 months post-
transplantation was 426 (Quartiles 1-3 [Q1-3], 246 to 687),
640 (Q1-3, 342 to 1135), and 643 (Q1-3, 351 to 1129),
respectively (Figure 3A). The median CD20þ B cell count/mL
Figure 1. (A) NRM and relapse incidence of the bortezomib study cohort. (B) Grades II to IV and III to IV acute GVHD incidence of the bortezomib study cohort. (C) OS
and PFS of the bortezomib study cohort.
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11), 120 (Q1-3, 50 to 304), and 194 (Q1-3, 73 to 309),
respectively Figure 3A). The median CD56þCD3 NK cell
count/mL at 1, 6, and 12months post-transplantationwas 252
(Q1-3, 193 to 371), 122 (Q1-3, 76 to 183), and 162 (Q1-3, 88 to
251), respectively (Figure 3A).
Regarding T subset reconstitution, the median total CD8þ
T cell count/mL at 1, 6, and 12 months post-transplantation
was 144 (Q1-3, 63 to 401), 224 (Q1-3, 113 to 647), and 266
(Q1-3, 126 to 461) (Figure 3B). The median total CD4þ T cell
count/mL at 1, 6, and 12months post-transplantationwas 218
(Q1-3, 143 to 340), 253 (Q1-3, 215 to 376), and 333 (Q1-3, 186
to 462), respectively (Figure 3C). CD4þ Treg and CD4þ and
CD8þ naive and memory T cell reconstitution was also
assessed (Figure 3B,C). Additionally, immunologic recovery
did not appear to be impaired in bortezomib-MMUD/MMRD
compared with bortezomib-MUD recipients (data not
shown).
DISCUSSION
Most adult hematologic malignancy patients who may
beneﬁt from HSCT lack an available sibling donor and are
usually transplanted from either a MUD or 1-locus HLA-
mismatched donors (with umbilical cord blood andhaploidentical donors also considered to be comparable). For
8/8 MUD, with improvements in DNA-based typing and
supportive care, survival outcomes are similar to MRD HSCT
[15,16]. However, MUDHSCT is still associatedwith increased
acute grades II to IV (52% versus 34%) and III to IV (21% versus
16%) GVHD and NRM (relative risk, 2.76; P< .01) [17]. The use
of1-locusmismatcheddonors adds risk.A retrospective study
of 2825 MAC HSCT recipients with myeloid disease predom-
inantly grafted with bone marrow from 7/8 versus 8/8 MUD
documented increased severe acute grades III to IV GVHD at
100 days (37% versus 28%; P < .001) and higher 1-year NRM
(45% versus 36%; P < .001), with poorer rates of 1-year
disease-free survival (38% versus 47%; P < .001) and OS (43%
versus 52%; P< .001) [2]. Amore recent retrospective analysis
of 1360 adult acute leukemia patients receiving bonemarrow
or PBSC grafts from 7/8 versus 8/8 HLA-matched donors also
documented increased 2-year NRM (34% to 38% versus 22% to
24%) and poorer 2-year disease-free survival for patients in
remission at time ofMACHSCT (39% to 41% versus 50% to52%)
[3]. Another retrospective analysis of 2646 adult patientswith
various hematologic malignancies (including lymphoma and
myeloma) receiving predominantly MAC transplantation
with PBSC grafts from 7/8 versus 8/8 HLA-matched donors
documented a higher rate of NRM (P< .01) and poorer rates of
Figure 2. (A) NRM and relapse incidence of the bortezomib-MUD versus -MMUD/MMRD cohorts. (B) PFS of the bortezomib-MUD versus -MMUD/MMRD cohorts. (C)
OS of the bortezomib-MUD versus -MMUD/MMRD cohorts.
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tively) [4]. These studies indicate that regardless of graft
source (bonemarrow, PBSC), worse outcomes are anticipated
in patients lacking 8/8 HLA-matched sibling donors because
of increased acute GVHD and NRM and poorer disease-free
survival and OS. Novel regimens to improve outcomes for
such patients would represent a major advance.
Bortezomib has immunomodulatory properties relevant
to allogeneic HSCT, and based on its encouraging results in
HLA-mismatched RIC HSCT, we prospectively evaluated a
regimen of short-course bortezomib plus tacrolimus and
MTX for MAC HSCT recipients lacking 8/8 HLA MRDs. Bor-
tezomib, limited to 3 doses early after transplantation
(days þ1, þ4, and þ7), appears to have little systemic
toxicity. No patient developed toxicities associated with
more prolonged bortezomib therapy (eg, neuropathy, colonic
necrosis), and no hepatic veno-occlusive disease was noted
despite the lack of PK-targeted busulfan conditioning.
Treatment-related toxicity after bortezomib-based MAC
HSCT is in the range previously reported for HLA-matched
transplantation.
The bortezomib-based MAC HSCT regimen appears to be
efﬁcacious. The 100-day cumulative incidence of grades II to
IV acute GVHD was 32%, and both MUD and MMUD/MMRDsurvival (rates of 2-year OS of 86% and 61%, respectively)
were substantially better than anticipated compared with
registry data [2-4,17]. However, retrospective registry out-
comes may not represent an adequate comparator. To place
our ﬁndings in context, we therefore compared the
bortezomib-MUD/MMUD/MMRD cohort with a near-
contemporaneous MUD MAC HSCT cohort receiving a T
cellereplete PBSC graft and standard-of-care tac/MTX GVHD
prophylaxis at our center. The cohort was similar to the
bortezomib-based cohort in most parameters, including
disease risk index and comorbidity scores. It differed with
regards to systematic use of cyclophosphamide (Cy)/TBI
(versus busulfan/ﬂudarabine) MAC, whose impact, if any,
remains uncertain. Although some retrospective and
prospective cohort studies indicate a survival beneﬁt
of busulfan- (primarily busulfan/Cy) versus TBI-based
(primarily Cy/TBI) MAC, other analyses fail to document
such beneﬁt, and a phase III randomized trial indicated
impaired survival of busulfan/ﬂudarabine (versus busulfan/
Cy) MAC HSCT, suggesting that use of ablative busulfan/-
ﬂudarabine conditioning in the bortezomib-based study
cohort is unlikely to provide a priori survival advantages
[18-21]. We document that despite the increased patient age
and HLA-mismatched donor use in the study cohort, the
Figure 3. Immune reconstitution of the bortezomib cohort. (A) Median values of absolute CD3þ T, CD20þ B, and CD56þCD3 NK cell counts. (B) Median values of
absolute CD8þ, CD8þ naive, and CD8þ memory cell counts. (C) Median values of absolute CD4þ, CD4þ naive, CD4þ memory, and CD4þ Treg cell counts.
J. Koreth et al. / Biol Blood Marrow Transplant 21 (2015) 1907e19131912bortezomib- and standard-of-care MUD MAC HSCT cohorts
had similar clinical outcomes of engraftment, NRM, relapse,
chronic GVHD, and survival, with a possible reduction in
acute GVHDwith bortezomib use.We also assessed the effect
of bortezomib on immunologic reconstitution, which
appeared to be robust in the study cohort.
Compared with both published retrospective analyses
and institutional MUD MAC control cohorts with standard
GVHD prophylaxis, outcomes of both MUD and 1-locus
mismatched MAC HSCT with the addition of bortezomib
appear to be promising. Although these phase II results are
encouraging, we caution that such retrospective and non-
randomized comparisons have inherent limitations, being
subject to bias and confounding, even in apparently well-
matched cohorts such as those described above. However,
they are useful in a hypothesis-generating context, providing
support for prospective randomized evaluation of
bortezomib-based MAC HSCT.
In the myeloablative context, a short-course bortezomib-
based regimen is safe, with evidence of efﬁcacy in acute
GVHD prophylaxis and with 1-locus mismatched survival
comparable with 8/8 MUD HSCT. Bortezomib appears to be
an active agent in MAC HSCT and is a candidate for pro-
spective randomized evaluation.ACKNOWLEDGMENTS
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